- The Alport disease is the second most common hereditary kidney disease and has a significant social and health impact.
- The study refers to individuals with the type of Alport syndrome that is probably the most frequent but also the least known and underdiagnosed.
- The aim of this research is to increase the understanding of the disease among nephrologists and to avoid misdiagnoses that can harm the patient.
Barcelona, April 7, 2021.- More than 60% of patients with Alport syndrome end up on dialysis and/or kidney transplantation without a diagnosis or with a misdiagnosis. With the aim of defining, for the first time, the clinical aspects of these patients and thus, increasing the understanding of the disease among nephrologists, the Fundació Puigvert has led a multicenter study published today in the prestigious journal American Journal of Kidney Diseases (AJKD).
The Alport disease is the second most common hereditary kidney disease and has a significant social and health impact. Specifically, in the research, the most extensive to date, 252 patients with the type of Alport syndrome that is probably the most frequent (the autosomal dominant) but also the least known and underdiagnosed participated.
From the analysis of these patients, who were studied at the Fundació Puigvert from hospitals across Spain between 2000 and 2019, some specific clinical characteristics are derived. “Among these defining traits of the disease, the average age of patients at the time they received dialysis or needed a transplant was 67 years, and the presence of blood in the urine was found in 92% of cases,” explains Dr. Roser Torra, a signatory of the study, along with Dr. Elisabet Ars, and the first author, Dr. Mónica Furlano, all professionals from the Fundació Puigvert.
Dr. Torra points out that for this type of disease “the ideal would be to always conduct a genetic study. However, currently, “the economic limitations of the healthcare system do not allow for this scenario, which is why, many times, a diagnosis of the disease cannot be reached”. “Being able to provide clues to nephrologists about this little-known variant of Alport disease can help achieve an accurate diagnosis and enable genetic counseling for families, as well as personalize treatment”, states the specialist.

Confusion with immunological kidney diseases
This type of Alport syndrome is frequently confused with immunological kidney diseases, such as glomerulonephritis, which require treatment with corticosteroids or immunosuppressants. “The misdiagnosis of this disease and the fact that administering inappropriate medication to the patient can harm their health”, indicates the specialist.
According to the nephrologist from the Fundació Puigvert, although there is currently no specific treatment for Alport disease, research in this area is progressing rapidly and there will surely be one in the near future.
In addition to the Fundació Puigvert, some of the hospitals across Spain that participated in the study include the Hospital de la Santa Creu i Sant Pau and the Hospital Clínic (Catalonia), the Hospital Clínic Universitari Verge de la Arrixaca (Murcia), the Hospital General Universitari de Castelló and the Hospital General de la Palma (Canary Islands), among many others.
